Physician profile
Andrew Ma
NPI 1477085041
$3,205.00
in general payments reported to CMS, 2019-2025
31 companies · $814 in 2025
The $814 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $260 · 2022: $908 · 2023: $961 · 2024: $262 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,037.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $644.37 | 2021-2023 | Endoflip |
| Abbvie INC. | $558.87 | 2021-2025 | |
| Gilead Sciences, INC. | $307.68 | 2022 | |
| Intercept Pharmaceuticals, INC. | $253.06 | 2022-2023 | Ocaliva |
| Mallinckrodt Hospital Products INC. | $228.59 | 2023-2024 | Terlivaz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.59 | 2022-2025 | Xifaxan, Relistor, Trulance |
| E.R. Squibb & Sons, L.L.C. | $125.10 | 2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $113.60 | 2022-2025 | Entyvio |
| Ardelyx, INC. | $96.62 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $83.64 | 2022-2025 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $70.87 | 2024-2025 | Iqirvo, Bylvay |
| Boston Scientific Corporation | $50.45 | 2021 | |
| Madrigal Pharmaceuticals | $48.90 | 2025 | Rezdiffra |
| Genzyme Corporation | $46.61 | 2025 | |
| Ferring Pharmaceuticals INC. | $40.27 | 2023-2025 | Rebyota |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $38.06 | 2025 | Omvoh |
| Exelixis INC. | $33.30 | 2023 | Cabometyx |
| Alnylam Pharmaceuticals INC. | $30.45 | 2023-2024 | Givlaari |
| Ironwood Pharmaceuticals, INC | $30.32 | 2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $25.52 | 2025 | Voquezna |
| Janssen Biotech, INC. | $24.24 | 2025 | Tremfya |
| Nestle Healthcare Nutrition INC. | $23.54 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $23.44 | 2024 | Caldolor |
| Regeneron Healthcare Solutions, INC. | $22.26 | 2025 | Dupixent |
| Novo Nordisk INC | $21.38 | 2025 | Wegovy |
| Organon LLC | $21.28 | 2023 | Hadlima, Renflexis |
| Teleflex LLC | $20.06 | 2024 | Solesta |
| Braintree Laboratories, INC. | $19.82 | 2025 | Suflave, Sutab |
| Aimmune Therapeutics, INC. | $19.05 | 2025 | Zenpep |
| Astrazeneca Pharmaceuticals LP | $15.98 | 2022 | |
| Exact Sciences Corporation | $15.08 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.